Ulimorelin

Modify Date: 2025-08-25 17:14:06

Ulimorelin Structure
Ulimorelin structure
Common Name Ulimorelin
CAS Number 842131-33-3 Molecular Weight 538.65300
Density N/A Boiling Point N/A
Molecular Formula C30H39FN4O4 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Ulimorelin


Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC50 of 29 nM and a Ki of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α1-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition[1][2][3].

 Names

Name D-Phenylalanine, (2S)-N-[(2R)-2-[2-(3-aminopropyl)phenoxy]propyl]-2-cyclopropylglycyl-N-methyl-D-alanyl-4-fluoro-, (3→1)-lactam
Synonym More Synonyms

 Ulimorelin Biological Activity

Description Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC50 of 29 nM and a Ki of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α1-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition[1][2][3].
Related Catalog
In Vivo Ulimorelin (TZP-101; 0.3-5 mg/kg; i.v.) causes a dose dependent increase in the numbers and amplitudes of phasic pressure waves recorded from the colorectum[1]. Ulimorelin (1, 3, 5 mg/kg; i.v.) causes a substantial and prolonged (~1 h) increase in colorectal propulsive activity and expulsion of colonic contents[1]. Ulimorelin (p.o.; 8 mg/kg) has a Cmax of 0.39 μM and a AUC of 82 μM•min for rats. Ulimorelin (i.v.; 2 mg/kg) has a T1/2 of 50 mins, a CL of 24 mL/min/kg, and a Vss of 1.7 L/kg for rats[3]. Animal Model: Male Sprague-Dawley rats[1] Dosage: 0.3, 1, 3, 5 mg/kg Administration: i.v. Result: Caused a dose dependent increase in the numbers and amplitudes of phasic pressure waves recorded from the colorectum.
References

[1]. Pustovit RV, et al. The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin. Neurogastroenterol Motil. 2014 Feb;26(2):264-71.

[2]. Broad J, et al. Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. Eur J Pharmacol. 2015 Apr 5;752:34-9. 

[3]. Hoveyda HR, et al. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. J Med Chem. 2011 Dec 22;54(24):8305-20.

 Chemical & Physical Properties

Molecular Formula C30H39FN4O4
Molecular Weight 538.65300
Exact Mass 538.29600
PSA 99.77000
LogP 3.52230
InChIKey WGYPAJVJMXQXTR-ABNZCKJZSA-N
SMILES CC1CNC(C2CC2)C(=O)N(C)C(C)C(=O)NC(Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1

 Synonyms

Ulimorelin
TZP 101
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.